Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) among top performers with a 6.81% increase on Wednesday. CEO Najat Khan to present at J.P. Morgan Healthcare Conference and Needham Growth Conference next week. Investors await earnings guidance for 2025, pipeline updates, and 2026 outlook. JPMorgan bullish on RXRX after positive results from REC-4881 clinical trial targeting Familial Adenomatous Polyposis, potential $1 billion in US sales.

Read more at Yahoo Finance: Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates